Meeting
2021 ASCO Annual Meeting
A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Authors
Nikhil Shukla
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Nikhil Shukla , Sandra K. Althouse , Susan Perkins , Muhammad Furqan , Ticiana Leal , Nasser H. Hanna , Greg Andrew Durm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03083808
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9073)
DOI
10.1200/JCO.2021.39.15_suppl.9073
Abstract #
9073
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya
Poster
2017 ASCO Annual Meeting
Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.
First Author: Paul Denis Leger
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
First Author: Antoine Italiano